Intralesional administration of recombinant Epidermal Growth Factor in patients with diabetic foot and risk of major amputation.
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2017
At a glance
- Drugs Recombinant epidermal growth factor (Primary)
- Indications Diabetic foot ulcer
- Focus Therapeutic Use
- 31 Jul 2013 Status changed from active, no longer recruiting to completed as reported by Cuban Clinical Trial Registry record.
- 13 Sep 2011 New trial record